Funding

Ratio Therapeutics

United States · Biotech

Developing best-in-class radiopharmaceuticals for cancer treatment

Visit ratiotx.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series C$70MBristol Myers Squibb — Role not disclosedCatalio Capital Management — Role not disclosedDuquesne Family Office — Role not disclosedEli Lilly and Company — Role not disclosedWasatch Group — Role not disclosed

Investors

Bristol Myers SquibbSeries CCatalio Capital ManagementSeries CDuquesne Family OfficeSeries CEli Lilly and CompanySeries CWasatch GroupSeries C

Coverage

Jul 31, 2026Ratio Therapeutics · Series C

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesratiotx.com ↗